Abstract
Cannabis use may be considered as an additional risk factor in a diathesis-stress model of schizophrenia where the risk of developing the illness would be higher in genetic vulnerable people. In this regard, much of the research on cannabis and psychosis is currently focusing on gene-environment interactions. The present review will focus on the interaction between genes and cannabis exposure in the development of psychotic symptoms and schizophrenia and the biological mechanisms of cannabis. Cannabis use has been shown to act together with other environmental factors such as childhood trauma or urbanicity producing synergistic dopamine sensitization effects. Studies on gene-environment interaction have mainly included genetic variants involved in the regulation of the dopaminergic system. The most promising genetic variants in this field are COMT, CNR1, BDNF, AKT1 and NRG1. Additionally, the interaction with other environmental factors and possible gene-gene interactions are considered in the etiological model.
Keywords: Schizophrenia, cannabinoids, gene-environment interaction, genetics, CB1, causality, COMT
Current Pharmaceutical Design
Title:Gene-Environment Interactions Underlying the Effect of Cannabis in First Episode Psychosis
Volume: 18 Issue: 32
Author(s): Jose Maria Pelayo-Teran, Paula Suarez-Pinilla, Nicholas Chadi and Benedicto Crespo-Facorro
Affiliation:
Keywords: Schizophrenia, cannabinoids, gene-environment interaction, genetics, CB1, causality, COMT
Abstract: Cannabis use may be considered as an additional risk factor in a diathesis-stress model of schizophrenia where the risk of developing the illness would be higher in genetic vulnerable people. In this regard, much of the research on cannabis and psychosis is currently focusing on gene-environment interactions. The present review will focus on the interaction between genes and cannabis exposure in the development of psychotic symptoms and schizophrenia and the biological mechanisms of cannabis. Cannabis use has been shown to act together with other environmental factors such as childhood trauma or urbanicity producing synergistic dopamine sensitization effects. Studies on gene-environment interaction have mainly included genetic variants involved in the regulation of the dopaminergic system. The most promising genetic variants in this field are COMT, CNR1, BDNF, AKT1 and NRG1. Additionally, the interaction with other environmental factors and possible gene-gene interactions are considered in the etiological model.
Export Options
About this article
Cite this article as:
Maria Pelayo-Teran Jose, Suarez-Pinilla Paula, Chadi Nicholas and Crespo-Facorro Benedicto, Gene-Environment Interactions Underlying the Effect of Cannabis in First Episode Psychosis, Current Pharmaceutical Design 2012; 18 (32) . https://dx.doi.org/10.2174/138161212802884609
DOI https://dx.doi.org/10.2174/138161212802884609 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Radiolabelled Quinoline Derivaties for the PET Imaging of Peripheral Benzodiazepine Receptor
Current Medical Imaging Vitamin D: Preventive and Therapeutic Potential in Parkinson’s disease
Current Drug Metabolism BDNF/NF-κB Signaling in the Neurobiology of Depression
Current Pharmaceutical Design FTD and ALS: A Tale of Two Diseases
Current Alzheimer Research Matter of Life and Death: the Pharmacological Approaches Targeting Apoptosis in Brain Diseases
Current Pharmaceutical Design Impaired Functional Connectivity of the Thalamus in Alzheimer’ s Disease and Mild Cognitive Impairment: A Resting-State fMRI Study
Current Alzheimer Research Single Amino Acid Repeats Connect Viruses to Neurodegeneration
Current Drug Discovery Technologies Central Nervous System Acting Drugs in Treatment of Migraine Headache
Central Nervous System Agents in Medicinal Chemistry Chronic Psychosocial Stress Exacerbates Impairment of Synaptic Plasticity in β-Amyloid Rat Model of Alzheimers Disease: Prevention by Nicotine
Current Alzheimer Research Adenosine A2A Receptor Antagonists and Parkinsons Disease: State of the Art and Future Directions
Current Pharmaceutical Design Copper Compounds in Anticancer Strategies
Current Medicinal Chemistry Cellular Mechanisms Underlying the Interaction between Cannabinoid and Opioid System
Current Drug Targets Brain Targeting of siRNA via Intranasal Pathway
Current Pharmaceutical Design On the Existence of a Global Molecular Network Enmeshing the Whole Central Nervous System: Physiological and Pathological Implications
Current Protein & Peptide Science Mitochondrial Dysfunction and Targeted Drugs: A Focus on Diabetes
Current Pharmaceutical Design Recent Advances in Progressive Supranuclear Palsy: A Review
Current Alzheimer Research Human Model Neurons in Studies of Brain Cell Damage and Neural Repair
Current Molecular Medicine Comparative Anatomy, Physiology and In Vitro Models of the Blood-Brain and Blood-Retina Barrier
Current Medicinal Chemistry - Central Nervous System Agents Vascular Lesion Thickness in the Lenticulostriate Artery Region Serves as a Biomarker for Early Neurological Deterioration
Current Neurovascular Research Genetic Bases of Progressive Supranuclear Palsy: The MAPT Tau Disease
Current Medicinal Chemistry